Decipher Genomics Resource for Intelligent Discovery

To prospectively evaluate the utility of genomic expression data as a tool to better characterize the tumors of individual patients, and to understand how genomic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Prostate Cancer Bladder Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Renal Cancer Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Sex eligibility

All sexes

Study type

Observational

About this study

Observational study involving the release of tumor genome-wide expression data generated by the Decipher assay which will be linked to clinical treatment and outcome data for patients in whom Decipher clinical testing was performed. The GRID database population will be used to characterize the genomics of cancer and discover or validate gene expression signatures that may be useful for understanding of the biology of the disease and implementing precision medicine approaches for cancer patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects that have had a Decipher clinical test

Treatment and study plan

Decipher Cancer Classifier

Other

The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA & CAP certified laboratory in San Diego, CA

Other names: Decipher Biopsy, Decipher RP, Decipher Bladder, Decipher Renal, Decipher Test

Primary outcomes

Link complete genomic RNA expression array data generated from Decipher testing with clinical data for patients who consent to participate.

Time frame: Through study completion, an average of 1 year

Role of genomic expression data in the biology of certain cancers

Sponsors and collaborators

Lead sponsor

GenomeDx Biosciences Corp

Industry

Collaborators

Veracyte, Inc.

Registry information

Official study title

Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery (GRID)® and Data Sharing Program

Acronym: GRID®

Important dates

Study start: 2015
Primary completion: 2030
Study completion: 2040
First posted: Nov 20, 2015
Registry last updated: Feb 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting